Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?

about

The Role of High-Mobility Group Box-1 and Its Crosstalk with Microbiome in Rheumatoid Arthritis.Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.

P2860

Q45804014-41E5C3CC-BA1E-4704-A8E2-94A5E0CC9D32 Q47191569-61B3CC98-D5A1-4258-9AF9-2B2A1E321192

P2860

Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?

Item

http://www.wikidata.org/entity/Q39042940

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Is there potential for therape ...... gents in rheumatoid arthritis?

@en

Is there potential for therape ...... gents in rheumatoid arthritis?

@nl

type

Item

label

Is there potential for therape ...... gents in rheumatoid arthritis?

@en

Is there potential for therape ...... gents in rheumatoid arthritis?

@nl

prefLabel

Is there potential for therape ...... gents in rheumatoid arthritis?

@en

Is there potential for therape ...... gents in rheumatoid arthritis?

@nl

P1476

Is there potential for therape ...... gents in rheumatoid arthritis?

@en

P2093

Dolors Soy

http://www.w3.org/2001/XMLSchema#string

Jordi Yagüe

http://www.w3.org/2001/XMLSchema#string

Mariona Pascal

http://www.w3.org/2001/XMLSchema#string

Virginia Ruíz

http://www.w3.org/2001/XMLSchema#string

P2860

Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis

Therapeutic monoclonal antibodies

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors.

Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries.

Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis.

Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis.

Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review.

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.

P304

962-975

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.13192

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

R Sanmarti

Carla Bastida

P577

2017-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27990682

http://www.w3.org/2001/XMLSchema#string

P932

5401978

http://www.w3.org/2001/XMLSchema#string

Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?

about

P2860

P2860

Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932